Identification of GCNT3 as a glycometabolism-associated biomarker in endometrial cancer
Da Ke, Wenzhe Li, Jun Xu, Xian He, Ya Wang, Jie Tan, Yaling Sun · 2026
Read Identification of GCNT3 as a glycometabolism-associated biomarker in endometrial cancer by Da Ke, Wenzhe Li, Jun Xu, Xian He, Ya Wang, Jie Tan, Yaling Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13376619.txt.
Description
Da Ke and six co-authors present a 2026 study naming a sugar-linked gene, GCNT3, as a marker in womb cancer. This cancer is rising, and diabetes raises its risk, hinting at shared metabolism. The team mined diabetes data sets and a large cancer cohort, then sifted candidate genes with three machine learning methods. Their pick, GCNT3, was checked in lab tests on eighty tumor samples against forty healthy ones.
The gene ran high in tumors. Patients with high levels lived longer and had lower-grade, earlier-stage disease, and the gene stayed an independent predictor after adjusting for age, grade, and stage. High levels also matched distinct immune patterns in the tumors and greater predicted sensitivity to two drugs. Computer docking suggested the drugs can bind the gene's product. The authors propose GCNT3 as a guide for prognosis and therapy choices.
Catalog record
| CREATOR | Da Ke, Wenzhe Li, Jun Xu, Xian He, Ya Wang, Jie Tan, Yaling Sun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 82 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |